{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:19:35Z","timestamp":1794853175289,"version":"4.9.1"},"reference-count":40,"publisher":"American Association of Avian Pathologists (AAAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Avian Diseases"],"published-print":{"date-parts":[[2022,12,20]]},"abstract":"<jats:p>Evaluaci\u00f3n de la eficacia de las vacunas recombinantes contra el virus de la enfermedad de Newcastle (vHVT-IBD-ND de doble inserto y vHVT-ND de inserto \u00fanico) seguidas de una vacunaci\u00f3n con una vacuna viva para la enfermedad de Newcastle contra un desaf\u00edo de la enfermedad de Newcastle velog\u00e9nico marroqu\u00ed en pollos de engorde comerciales. El advenimiento de la tecnolog\u00eda de vacunas recombinantes (vHVT) del virus herpes del pavo (HVT) ha provocado una mejora en la prevenci\u00f3n y el control de varias enfermedades av\u00edcolas. El objetivo de este estudio fue comparar, en condiciones experimentales, la protecci\u00f3n conferida por diferentes programas vacunales basados en una vacuna recombinante HVT con doble inserto (bursitis infecciosa [EII] y enfermedad de Newcastle [ND]) (vHVT-IBD-ND) y una vacuna recombinante HVT con inserto \u00fanica (vHVT-ND) seguida de una vacunaci\u00f3n con una vacuna para Newcastle viva aplicada en el d\u00eda 1 o en los d\u00edas 1 y 14. Pollos de engorde comerciales se vacunaron con las vacunas recombinantes del virus de la enfermedad de Newcastle por v\u00eda subcut\u00e1nea al d\u00eda de edad, en la incubadora y se expusieron a los 30 d\u00edas de edad utilizando la cepa JEL viscerotr\u00f3pica velog\u00e9nica del virus de la enfermedad de Newcastle de Marruecos. Los resultados mostraron que la vacuna evaluada indujo una protecci\u00f3n cl\u00ednica del 95% al 100% contra la mortalidad y los signos cl\u00ednicos. La respuesta inmune humoral a la vacunaci\u00f3n se detect\u00f3 a partir de las 3 semanas de edad mediante ensayo inmunoabsorbente ligado a enzimas y pruebas de inhibici\u00f3n de la hemaglutinaci\u00f3n. La excreci\u00f3n del virus de Newcastle de desaf\u00edo se redujo significativamente en las aves vacunadas en comparaci\u00f3n con los controles. La reducci\u00f3n significativa de la eliminaci\u00f3n cloacal sugiere que la vacuna vHVT-IBD-ND estimula activamente la inmunidad contra el virus de Newcastle de desaf\u00edo analizado. No se encontraron diferencias significativas entre los programas de vacunaci\u00f3n basados en vHVT-IBD-ND o en vHVT-ND.<\/jats:p>","DOI":"10.1637\/aviandiseases-d-22-00045","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:07:05Z","timestamp":1671584825000},"page":"396-403","source":"Crossref","is-referenced-by-count":4,"title":["Assessing the Efficacy of Recombinant Newcastle Disease Virus Vaccines (Double-Insert vHVT-IBD-ND and Single-Insert vHVT-ND) Followed by a Vaccination with a Live Newcastle Disease Vaccine Against a Moroccan Velogenic Newcastle Disease Challenge in Commercial Broilers"],"prefix":"10.1637","volume":"66","author":[{"given":"Siham","family":"Fellahi","sequence":"first","affiliation":[{"name":"D\u00e9partement de Pathologie et Sant\u00e9 Publique V\u00e9t\u00e9rinaire, Institut Agronomique et V\u00e9t\u00e9rinaire Hassan II, Rabat, Morocco (10000)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Rawi","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim animal health, 29, avenue Tony Garnier, 69007, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Fagrach","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie et Sant\u00e9 Publique V\u00e9t\u00e9rinaire, Institut Agronomique et V\u00e9t\u00e9rinaire Hassan II, Rabat, Morocco (10000)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamiae","family":"Berrada","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie et Sant\u00e9 Publique V\u00e9t\u00e9rinaire, Institut Agronomique et V\u00e9t\u00e9rinaire Hassan II, Rabat, Morocco (10000)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Delvecchio","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim animal health, 29, avenue Tony Garnier, 69007, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charifa Drissi","family":"Touzani","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie et Sant\u00e9 Publique V\u00e9t\u00e9rinaire, Institut Agronomique et V\u00e9t\u00e9rinaire Hassan II, Rabat, Morocco (10000)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed EL","family":"Houadfi","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie et Sant\u00e9 Publique V\u00e9t\u00e9rinaire, Institut Agronomique et V\u00e9t\u00e9rinaire Hassan II, Rabat, Morocco (10000)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Kichou","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie et Sant\u00e9 Publique V\u00e9t\u00e9rinaire, Institut Agronomique et V\u00e9t\u00e9rinaire Hassan II, Rabat, Morocco (10000)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lemiere","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim animal health, 29, avenue Tony Garnier, 69007, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1212","reference":[{"key":"32","doi-asserted-by":"crossref","unstructured":"S Kumar, B Nayak, PL Collins, et al.  \"J Virol.\"  85, \"Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens.\" 6521 (2011)","DOI":"10.1128\/JVI.00367-11"},{"key":"11","doi-asserted-by":"crossref","unstructured":"V Palya, T Tatar-Kis, T Mato, et al.  \"Vet Immunol Immunopathol.\"  158, \"Onset and long-term duration of immunity provided by a single vaccination with a turkey herpesvirus vector ND vaccine in commercial layers.\" 105 (2014)","DOI":"10.1016\/j.vetimm.2013.11.008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"JC Dortmans, G Koch, PJ Rottier, et al.  \"Vet Res.\"  42, \"Virulence of Newcastle disease virus: what is known so far?\" 122 (2011)","DOI":"10.1186\/1297-9716-42-122"},{"key":"1","doi-asserted-by":"crossref","unstructured":"DJ Alexander, EW Aldous, CM Fuller,  \"Avian Pathol.\"  41, \"The long view: a selective review of 40 years of Newcastle disease research.\" 329 (2012)","DOI":"10.1080\/03079457.2012.697991"},{"key":"8","doi-asserted-by":"crossref","unstructured":"F Perozo, R Marcano, CL Afonso,  \"J Clin Microbiol.\"  50, \"Biological and phylogenetic characterization of a genotype VII Newcastle disease virus from Venezuela: efficacy of field vaccination.\" 1204 (2012)","DOI":"10.1128\/JCM.06506-11"},{"key":"2","unstructured":"DJ Alexander  and DE Swayne  \"A laboratory manual for the isolation and identification of avian pathogens.\"  4, \"Newcastle disease virus and other avian paramyxoviruses.\" 156 (1998)"},{"key":"3","doi-asserted-by":"crossref","unstructured":"MS. Galinski,  \"Adv Virus Res.\"  39, \"Paramyxoviridae: transcription and replication.\" 129 (1991)","DOI":"10.1016\/S0065-3527(08)60794-0"},{"key":"4","unstructured":"RA Lamb  and D Kolakofsky  \"Fields virology.\"  \"Paramyxoviridae: the viruses and their replication.\" (1996)"},{"key":"6","doi-asserted-by":"crossref","unstructured":"G Cattoli, L Susta, C Terregino, et al.  \"J Vet Diagn Invest.\"  23, \"Newcastle disease: a review of field recognition and current methods of laboratory detection.\" 637 (2011)","DOI":"10.1177\/1040638711407887"},{"key":"7","doi-asserted-by":"crossref","unstructured":"DG Bwala, C Abolnik, A van Wyk, et al.  \"J S Afr Vet Assoc.\"  80, \"Efficacy of a genotype 2 Newcastle disease vaccine (Avinew\u00ae) against challenge with highly virulent genotypes 5d and 3d.\" 174 (2009)","DOI":"10.4102\/jsava.v80i3.197"},{"key":"9","doi-asserted-by":"crossref","unstructured":"KM Dimitrov, CL Afonso, Q Yu, et al.  \"Vet Microbiol.\"  206, \"Newcastle disease vaccines\u2014a solved problem or a continuous challenge?\" 126 (2017)","DOI":"10.1016\/j.vetmic.2016.12.019"},{"key":"13","doi-asserted-by":"crossref","unstructured":"JR Dunn, KM Dimitrov, PJ Miller, et al.  \"Avian Dis.\"  63, \"Evaluation of protective efficacy when combining turkey herpesvirus\u2013vector vaccines.\" 75 (2019)","DOI":"10.1637\/11979-092818-Reg.1"},{"key":"#cr-split#-14.1","unstructured":"V Palya, T Tatar-Kis, T Mato, et al. \"Proceedings of the Annual Meeting of the American Association of Avian Pathologists. 2010 Aug 2"},{"key":"#cr-split#-14.2","unstructured":"Atlanta (GA).\" \"Interference between different HVT-vectored vaccines applied subcutaneously at day-old in commercial broiler.\" (2010)"},{"key":"16","unstructured":"\"Vectormune ND suspension and solvent for suspension for injection for chickens\u2014summary of product characteristics.\"  (2022)"},{"key":"17","unstructured":"D. Senne,  \"A laboratory manual for the isolation, identification and characterization of avian pathogens.\"  \"Virus propagation in embryonating eggs L.\" 204 (2008)"},{"key":"18","doi-asserted-by":"crossref","unstructured":"M Younus, A Maqbool, I Khan, et al.  \"Pak J Zool.\"  49, \"Pathological alterations during co-infection of Newcastle disease virus with Escherichia coli in broiler chicken.\" 1953 (2017)","DOI":"10.17582\/journal.pjz\/2017.49.6.1953.1961"},{"key":"19","unstructured":"\"Avian influenza (including infection with high pathogenicity avian influenza viruses).\"  (2021)"},{"key":"21","doi-asserted-by":"crossref","unstructured":"S Marangon  and L Busani  \"Rev Sci Tech Off Int Epizoot.\"  26, \"The use of vaccination in poultry production.\" 265 (2006)","DOI":"10.20506\/rst.26.1.1742"},{"key":"22","doi-asserted-by":"crossref","unstructured":"M Bublot, N Pritchard, FX Le Gros, et al.  \"Comp Pathol.\"  1, \"Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titred maternally derived antibody.\" 81 (2007)","DOI":"10.1016\/j.jcpa.2007.04.017"},{"key":"#cr-split#-25.1","unstructured":"J Cruz-Coy, S Cook, L Gergen, et al. \"Annual Meeting of the American Association of Avian Pathologists. 2017 Jul 21-25"},{"key":"#cr-split#-25.2","unstructured":"Indianapolis (IN).\" \"Double recombinant herpesvirus of turkey for protection against diseases caused by Newcastle disease virus, infectious bursal disease virus and Marek's disease virus. Abstract.\" (2017)"},{"key":"26","doi-asserted-by":"crossref","unstructured":"D Maekawa, SM Riblet, P Whang, et al.  \"Avian Dis.\"  65, \"A cell line adapted infectious virus strain (BdeltaORFC) for in ovo and hatchery spray vaccination alone or in combination with a recombinant HVT-LT vaccine.\" 500 (2021)","DOI":"10.1637\/aviandiseases-D-20-00050"},{"key":"28","doi-asserted-by":"crossref","unstructured":"N Charoenvisal, B Supannamoke, R Koopman,  \"Thai J Vet Med.\"  48, \"Efficacy of different vaccination programs of recombinant HVT-NDV vaccine against genotype VII NDV challenge in broiler chickens.\" 603 (2018)","DOI":"10.56808\/2985-1130.2952"},{"key":"29","unstructured":"NK Armour  and M Garc\u00eda  \"The poultry informed professional.\"  \"Current and future applications of viral-vectored recombinant vaccines in poultry.\" 1 (2014)"},{"key":"#cr-split#-30.1","unstructured":"M. Paniago, \"Proceedings of the 65th Western Poultry Disease Conference. 2016 Apr 24-27"},{"key":"#cr-split#-30.2","unstructured":"Vancouver (Canada).\" \"Assessment of the protection induced by a vector rHVT-F vaccine against different genotypes of Newcastle disease virus.\" 00 (2016)"},{"key":"31","doi-asserted-by":"crossref","unstructured":"F Rauw, S Van Borm, S Welby, et al.  \"Avian Pathol.\"  44, \"Quantification of rHVT-F genome load in feather follicles by specific real-time qPCR as an indicator of NDV-specific humoral immunity induced by day-old vaccination in SPF chickens.\" 154 (2015)","DOI":"10.1080\/03079457.2015.1018869"},{"key":"#cr-split#-33.1","unstructured":"G. Slacum, \"Proceeding of 68th Western Poultry Disease Conference. 2019 Apr 3-6"},{"key":"#cr-split#-33.2","unstructured":"Puerto Vallarta (Mexico).\" \"Vaccination monitoring of recombinant HVT vectored vaccines for NDV using a NDV-F ELISA.\" 254 (2019)"},{"key":"#cr-split#-34.1","unstructured":"R. Soares, \"Proceedings of the International Seminar on Poultry Diseases. 2015 Dec 14-15"},{"key":"#cr-split#-34.2","unstructured":"Faisalabad (Pakistan).\" \"Key aspects to be considered on the monitoring and testing of flocks vaccinated with rHVT-ND.\" 18 (2015)"},{"key":"35","doi-asserted-by":"crossref","unstructured":"SK Reddy, JM Sharma, J Ahmad, et al.  \"Vaccine.\"  14, \"Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific pathogen free chickens.\" 469 (1996)","DOI":"10.1016\/0264-410X(95)00242-S"},{"key":"20","doi-asserted-by":"crossref","unstructured":"MG Wise, DL Suarez, BS Seal, et al.  \"J Clin Microbiol.\"  42, \"Development of a real-time reverse-transcription PCR for detection of Newcastle disease virus RNA in clinical samples.\" 329 (2004)","DOI":"10.1128\/JCM.42.1.329-338.2004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"M Esaki, A Godoy, JK Rosenberger, et al.  \"Avian Dis.\"  57, \"Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine.\" 750 (2013)","DOI":"10.1637\/10540-032613-Reg.1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"RW Morgan, J Gelb, CS Schreurs, et al.  \"Avian Dis.\"  36, \"Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein.\" 858 (1992)","DOI":"10.2307\/1591544"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Y Gardin, V Palya, KM Dorsey, et al.  \"Avian Dis.\"  60, \"Experimental and field results regarding immunity induced by a recombinant turkey herpesvirus H5 vector vaccine against H5N1 and other H5 highly pathogenic avian influenza virus challenges.\" 232 (2016)","DOI":"10.1637\/11144-050815-ResNote"},{"key":"23","doi-asserted-by":"crossref","unstructured":"K Andoh, K Yamazaki, Y Honda, et al.  \"Arch Virol.\"  162, \"Turkey herpesvirus with an insertion in the UL3-4 region displays an appropriate balance between growth activity and antibody-eliciting capacity and is suitable for the establishment of a recombinant vaccine.\" 931 (2017)","DOI":"10.1007\/s00705-016-3181-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"L Gergen, S Cook, B Ledesma, et al.  \"Avian Pathol.\"  48, \"A double recombinant herpes virus of turkeys for the protection of chickens against Newcastle, infectious laryngotracheitis and Marek's diseases.\" 45 (2019)","DOI":"10.1080\/03079457.2018.1546376"},{"key":"15","doi-asserted-by":"crossref","unstructured":"HL Ferreira, AM Reilley, D Goldenberg, et al.  \"Vaccine.\"  38, \"Protection conferred by commercial NDV live attenuated and double recombinant HVT vaccines against virulent California 2018 Newcastle disease virus (NDV) in chickens.\" 5507 (2020)","DOI":"10.1016\/j.vaccine.2020.06.004"}],"container-title":["Avian Diseases"],"original-title":[],"link":[{"URL":"https:\/\/bioone.org\/journals\/avian-diseases\/volume-66\/issue-4\/aviandiseases-D-22-00045\/Assessing-the-Efficacy-of-Recombinant-Newcastle-Disease-Virus-Vaccines-Double\/10.1637\/aviandiseases-D-22-00045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:28:54Z","timestamp":1793428134000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/avian-diseases\/volume-66\/issue-4\/aviandiseases-D-22-00045\/Assessing-the-Efficacy-of-Recombinant-Newcastle-Disease-Virus-Vaccines-Double\/10.1637\/aviandiseases-D-22-00045.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1637\/aviandiseases-d-22-00045","relation":{},"ISSN":["0005-2086","1938-4351"],"issn-type":[{"value":"0005-2086","type":"print"},{"value":"1938-4351","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]}}}